Journal of Drugs in Dermatology最新文献

{"title":"Sunscreens: Mechanisms and Safety in Depth.","authors":"Natalia V Chałupczak, Peter A Lio","doi":"10.36849/JDD.8102","DOIUrl":"https://doi.org/10.36849/JDD.8102","url":null,"abstract":"<p><p>Sunscreens play an essential role in preventing skin cancer and photoaging. Nevertheless, concerns about their systemic absorption and environmental impacts persist. In this extensive literature review, we discuss the mechanisms of action, efficacy, and safety concerns related to sunscreen use, aiming to clarify current understandings and dispel prevalent myths. Despite ongoing debates regarding certain ingredients, the scientific consensus supports the use of sunscreens as a critical defense against ultraviolet (UV) radiation. Continued research is necessary to address safety concerns and to refine sunscreen formulations for optimal protection and minimal adverse effects. J Drugs Dermatol. 2025;24(2):142-146. doi:10.36849/JDD.8102.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 2","pages":"142-146"},"PeriodicalIF":1.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Review of the Safety and Efficacy of Deucravacitinib for Plaque Psoriasis: An Expert Consensus Panel.","authors":"Milaan Shah, Joshua Burshtein, Danny Zakria, Erin Boh, Michael Cameron, Brad Glick, Alexandra Golant, George Han, Sylvia Hsu, Benjamin Lockshin, Andrea Neimann, David Rosmarin, Mark Lebwohl","doi":"10.36849/JDD.8616","DOIUrl":"https://doi.org/10.36849/JDD.8616","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis is a chronic, inflammatory disease associated with numerous negative physical and psychosocial impacts. Deucravacitinib is a novel, selective TYK2 inhibitor approved by the FDA for the treatment of moderate-to-severe plaque psoriasis in adults. Deucravacitinib has established efficacy and safety through several clinical trials, but many clinicians are unfamiliar with its safety profile given the lack of formal guidelines. Thus, this expert consensus panel aims to provide clinical recommendations on the efficacy, safety, and appropriate laboratory monitoring for deucravacitinib.</p><p><strong>Methods: </strong>A comprehensive literature search of PubMed, Scopus, and Google Scholar was completed for English-language original research articles on the efficacy and safety of deucravacitinib. A panel of 10 dermatologists with expertise in managing psoriasis reviewed the relevant literature and crafted consensus statements regarding the efficacy, safety, and recommended laboratory monitoring for deucravacitinib. Using a modified Delphi process, each statement received supermajority approval and was assigned a strength of recommendation using the Strength of Recommendation Taxonomy (SORT) criteria.</p><p><strong>Results: </strong>The literature search resulted in 101 articles that met search criteria. After screening the articles for relevance to the discussion topic, 14 articles were selected and distributed to the panelists for review prior to the roundtable discussion. The panel unanimously voted to adopt 6 consensus statements and recommendations, 5 of which were given a strength of \"A,\" 0 were given a strength of \"B,\" and 1 was given a strength of \"C.\"</p><p><strong>Conclusion: </strong>Deucravacitinib is an effective treatment for plaque psoriasis that is well-tolerated and has an excellent safety profile. The 6 consensus statements created by the panel provide expert recommendations regarding the efficacy, safety, and appropriate laboratory monitoring for deucravacitinib. The expert panel also concludes that deucravacitinib has a superior safety profile to traditional JAK inhibitors. After reviewing the clinical trials, the panel did not find evidence of a causal role for deucravacitinib in inducing laboratory abnormalities and did not recommend baseline and ongoing laboratory monitoring for patients treated with deucravacitinib. J Drugs Dermatol. 2025;24(2):147-155. doi:10.36849/JDD.8616.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 2","pages":"147-155"},"PeriodicalIF":1.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antioxidant, Keratolytic, and Hydrating Treatment for Seborrheic Keratoses.","authors":"William V Stoecker, Jonathan Kopel, Navin Geria, Nasim Nosoudi","doi":"10.36849/JDD.7977","DOIUrl":"https://doi.org/10.36849/JDD.7977","url":null,"abstract":"<p><strong>Background: </strong>Seborrheic keratoses (SKs) are the most common skin lesions to prompt visits to a dermatologist. Patients may be concerned about unsightly appearance, irritation, or the possibility of skin cancer. They frequently ask if there is a topical treatment for these lesions.</p><p><strong>Objective: </strong>We sought to determine an effective topical formula to improve the appearance of seborrheic keratosis and test the formula in a pilot observational study on a small number of patients.</p><p><strong>Methods and materials: </strong>A topical mixture of antioxidants, hydrating, and keratolytic agents was applied to five SKs on four patients in a private dermatology clinic. Antioxidants included green walnut hull extract, green tea, ellagic acid from pomegranate, curcumin in turmeric, and rosemary. Urea, salicylic acid, zinc lactate, and glycerin promoted hydration and keratolysis. Lesions were covered with 3M Nexcare&reg; dressings. Softened SK debris was removed with an emery board.</p><p><strong>Results: </strong>The appearance of the SKs was improved in five cases.</p><p><strong>Conclusions and relevance: </strong>A 5-to-17-day course of a topical mixture composed of antioxidant, keratolytic, and hydrating agents, followed by scooping of softened SK, improved the appearance of 5 SKs. The topical antioxidant mixture reported in this pilot study warrants further investigation. J Drugs Dermatol. 2025;24(2):183-187. doi:10.36849/JDD.7977.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 2","pages":"183-187"},"PeriodicalIF":1.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dupilumab Treatment Improves Lichenification in Atopic Dermatitis in Different Age and Racial Groups.","authors":"Emma Guttman-Yassky, Norito Katoh, Michael J Cork, Jared Jagdeo, Andrew F Alexis, Zhen Chen, Noah A Levit, Ana B Rossi","doi":"10.36849/JDD.85852","DOIUrl":"https://doi.org/10.36849/JDD.85852","url":null,"abstract":"<p><strong>Background: </strong>Lichenification, common in moderate to severe atopic dermatitis (AD) at any age, is often difficult to treat. This analysis assessed dupilumab vs placebo in AD lichenification by age and race-defined groups.</p><p><strong>Methods: </strong>This post hoc analysis included pooled data from five clinical trials of dupilumab (NCT03054428, NCT03345914, NCT02277743, NCT02277769, NCT02395133), including 1,997 patients aged 6 to 88 years of all races with moderate to severe AD.</p><p><strong>Results: </strong>Placebo/dupilumab randomized groups analyzed by age (n=1,535) included 123/244 children, 85/166 adolescents, and 460/457 adults; groups analyzed by self-reported racial background (n=1,902) included 132/234 Asian, 74/112 Black/African American, and 427/923 White patients. Dupilumab treatment resulted in nominally significant reductions vs placebo in Global Individual Signs Score lichenification from week 1 (adults/adolescents) or week 2 (children) through week 16. Lichenification measured by SCORing Atopic Dermatitis and Eczema Area and Severity Index improved similarly. By week 16, dupilumab significantly improved lichenification, with nominal significance vs placebo across all racial groups.</p><p><strong>Conclusion: </strong>Dupilumab treatment resulted in rapid and sustained improvement in lichenification across anatomic regions in all ages. Lichenification improved to a similar extent across racial groups. J Drugs Dermatol. 2025;24(2):167-173. doi:10.36849/JDD.8585R1.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 2","pages":"167-173"},"PeriodicalIF":1.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing Adherence, Side Effects, and Satisfaction in Oral and Topical Minoxidil: A Cross-Sectional Study.","authors":"Sonja Kobayashi, Lucy Rose, Abena Minta, Stephanie Trovato, Brittany Dulmage","doi":"10.36849/JDD.8424","DOIUrl":"https://doi.org/10.36849/JDD.8424","url":null,"abstract":"<p><p>Hair loss disorders negatively impact quality of life. Topical and oral minoxidil are hair loss therapeutics that require daily use to achieve sustained benefits. Patients on topical minoxidil often report aesthetic and discomfort concerns (eg, greasy hair), which may limit adherence. Oral minoxidil is not FDA-approved for alopecia and carries a higher risk of systemic side effects. Efficacy between the 2 is similar. However, the impact of the route of administration on patient adherence and satisfaction remains unclear. Our study investigates whether topical or oral minoxidil yields greater adherence and satisfaction while comparing side effects. A survey was distributed to patients on minoxidil (n=50, response rate 98.0%) to assess ease of treatment, adherence, satisfaction, and side effects. Patients on oral minoxidil reported greater ease of treatment (P=0.0004) and styling their hair on treatment (P=0.0112). Fewer patients on oral minoxidil stopped treatment due to difficulty of use (0% vs 18.8%, P=0.0076). Oral patients missed less treatment days (x=0.15 vs x=1.2, P=0.0022) and reported greater satisfaction in hair volume (P=0.0098) and change of hair (P=0.0159). Side effects were similar, except for a higher incidence of hypertrichosis among patients on oral minoxidil (48.5% vs 6.25%, P=0.0015). These findings suggest that oral minoxidil is superior to topical in terms of ease of use, adherence, and satisfaction without increasing systemic side effects. By circumventing scalp application, oral minoxidil reduces the treatment burden and avoids the aesthetic and discomfort complaints that limit adherence. When establishing treatment plans, physicians should consider patient experience and its impact on adherence. J Drugs Dermatol. 2025;24(2):131-133. doi:10.36849/JDD.8424.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 2","pages":"131-133"},"PeriodicalIF":1.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Review of Management Strategies for Erosive Pustular Dermatosis of the Scalp.","authors":"Nikita Menta, Savanna I Vidal, Adam Friedman","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 2","pages":"217-218"},"PeriodicalIF":1.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Quality and Reliability of Most-Viewed TikTok Videos About Spironolactone.","authors":"Savanna I Vidal, Peter Baek, Nikita Menta, Emily Murphy, Adam Friedman","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 2","pages":"e7-e9"},"PeriodicalIF":1.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Future of Machine Learning Enabled Technologies for Hair Loss Treatment.","authors":"Hafsah Sheikh, Eric McMullen, Kyle Storm, Jeff Donovan","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 2","pages":"e10"},"PeriodicalIF":1.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Visual Assessment Tools and Therapeutic Implications for Acanthosis Nigricans.","authors":"David Bitterman, Jennifer Y Wang, Kayla Zafar, Paras Patel, John McGovern, Evan Austin, Jared Jagdeo","doi":"10.36849/JDD.8168","DOIUrl":"https://doi.org/10.36849/JDD.8168","url":null,"abstract":"<p><p>Acanthosis nigricans significantly impacts individuals with skin of color. No United States Food and Drug Administration (FDA)-approved therapy exists for acanthosis nigricans. This review evaluates visual scoring tools for assessing acanthosis nigricans severity, focusing on their utility in monitoring therapy response in clinical trials. Our analysis included five visual scoring tools and revealed that the Acanthosis Nigricans Scoring Chart is the most effective tool for monitoring acanthosis nigricans severity in response to therapy, while the Acanthosis Nigricans Area and Severity Index also remains a strong option for split-neck trials. Future tools should match severity scores with detailed descriptions and images. The inclusion of lesion size in future assessment tools requires careful consideration due to variable reliability among evaluators. This study highlights the need for a universally accepted acanthosis nigricans severity assessment tool. Advancing such methods is crucial to developing effective treatments and addressing healthcare disparities, particularly for individuals with skin of color. J Drugs Dermatol. 2025;24(2):156-161. doi:10.36849/JDD.8168R1.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 2","pages":"156-161"},"PeriodicalIF":1.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Unusual Case of Psoriasiform Dermatitis Treated With Dual Biologic Therapy and Literature Review.","authors":"Yvonne Nong, Justin W Marson, Kristina Derrick, Edward Heilman, Jane Schneider, Jessica L Feig, Daniel M Siegel","doi":"10.36849/JDD.8382","DOIUrl":"https://doi.org/10.36849/JDD.8382","url":null,"abstract":"<p><p>Previously believed to be of distinct immunopathogenesis, atopic dermatitis (AD) and psoriasis (PsO) spectrum may permit immunologic shifts to favor the opposing inflammatory states following biologic treatment. Cases of AD that developed following PsO biologics are increasingly reported in the literature. While biologic monotherapy is becoming more widely available, dual biologic therapies have been understudied. Here, we present a patient with biopsy-confirmed PsO who developed psoriasiform spongiotic dermatitis following anti-IL-17A initiation who responded to combination anti-IL-23 and anti-IL-4Ra therapy and discussed the PsO-AD immunologic spectrum and use of dual biologic therapies. J Drugs Dermatol. 2025;24(2):207-211. doi:10.36849/JDD.8382R1.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 2","pages":"207-211"},"PeriodicalIF":1.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}